Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets

Oncotarget

Volumn 6, Issue 6, 2015, Pages 3507-3518

  Chang, Katherine ^a,b   Karnad, Anand ^a,b   Zhao, Shujie ^a   Freeman, James W ^a,b,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

c Met; Met inhibitors; RON kinase

Indexed keywords

AMG 337; C MET AND RECEPTOR ORIGINATED FROM NANTES; CABOZANTINIB; CAPMATINIB; CRIZOTINIB; ENCORAFENIB; ERLOTINIB; FORETINIB; GOLVATINIB; LY 2801653; MACROPHAGE ACTIVATING FACTOR; MGCD 65; NARNATUMAB; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; RON PROTEIN;

ARTICLE; BINDING AFFINITY; C MET GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TARGETING; RON GENE; SOLID TUMOR; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; UPREGULATION; ANIMAL; DISEASE COURSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84924243839     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3420     Document Type: Article

References (90)

1. Wang MH, Zhang R, Zhou YQ, Yao HP. Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. Journal of biomedical research. 2013;27(5):345-56. Epub 2013/10/03.
2. Gherardi E, Love CA, Esnouf RM, Jones EY. The sema domain. Current opinion in structural biology. 2004;14(6):669-78. Epub 2004/12/08.
3. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends in molecular medicine. 2010;16(1):37-45. Epub 2009/12/25.
4. Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer letters. 2007;257(2):157-64. Epub 2007/09/25.
5. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. Journal of cellular physiology. 2007;213(2):316-25. Epub 2007/07/04.
6. Boccaccio C, Comoglio PM. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer research. 2013;73(11):3193-9. Epub 2013/05/23.
7. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Annals of surgical oncology. 2005;12(4):273-81. Epub 2005/04/14.
8. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, et al. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 2007;109(6):1030-9. Epub 2007/02/22.
9. Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harbor perspectives in biology. 2013;5(7). Epub 2013/07/03.
10. Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43(2):183-9. Epub 2014/02/13.
11. McClaine RJ, Marshall AM, Wagh PK, Waltz SE. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia. 2010;12(8):650-8. Epub 2010/08/07.
12. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M. Breast Cancer-Derived Bone Metastasis can be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET knockdown. Molecular cancer therapeutics. 2011. Epub 2011/10/27.
13. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003;9(4):1480-8. Epub 2003/04/10.
14. Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A, Wang J, et al. Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. The Journal of biological chemistry. 2008;283(17):11293-301. Epub 2008/03/04.
15. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141(6):2218-27 e5. Epub 2011/09/29.
16. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-43. Epub 2007/04/28.
17. Han CB, Ma JT, Li F, Zhao JZ, Jing W, Zhou Y, et al. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer letters. 2011. Epub 2011/10/11.
18. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer letters. 2008;265(2):258-69. Epub 2008/04/09.
19. Peace BE, Hughes MJ, Degen SJ, Waltz SE. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene. 2001;20(43):6142-51. Epub 2001/10/11.
20. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes, chromosomes & cancer. 2008;47(12):1025-37. Epub 2008/08/19.
21. Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene. 1998;17(6):741-9. Epub 1998/08/26.
22. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer letters. 2005;225(1):1-26. Epub 2005/06/01.
23. Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anti-cancer agents in medicinal chemistry. 2009;9(2):221-9. Epub 2009/02/10.
24. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15(7):2207-14. Epub 2009/03/26.
25. Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, Deshmukh SV, et al. Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. Journal of medicinal chemistry. 2011;54(12):4092-108. Epub 2011/05/26.
26. Li Z, Yao H, Guin S, Padhye SS, Zhou YQ, Wang MH. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. International journal of oncology. 2010;37(2):473-82. Epub 2010/07/03.
27. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta pharmacologica Sinica. 2010;31(9):1181-8. Epub 2010/08/10.
28. Yap TA, Sandhu SK, Alam SM, de Bono JS. HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine. Current drug targets. 2011. Epub 2011/07/23.
29. Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer research. 2011;71(5):1945-55. Epub 2011/01/08.
30. Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nature reviews Cancer. 2013;13(7):466-81. Epub 2013/06/26.
31. Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, et al. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. The Journal of biological chemistry. 2011;286(37):32762-74. Epub 2011/07/26.
32. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. The EMBO journal. 1994;13(15):3524-32. Epub 1994/08/01.
33. Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, et al. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 2014;5(13):4855-67. Epub 2014/06/24.
34. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine & growth factor reviews. 2002;13(1):41-59. Epub 2001/12/26.
35. Chen XP, Ren XP, Lan JY, Chen YG, Shen ZJ. Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice. Molecular biology reports. 2014;41(3):1247-56. Epub 2014/01/29.
36. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochemical and biophysical research communications. 1984;122(3):1450-9. Epub 1984/08/16.
37. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 1991;6(4):501-4. Epub 1991/04/01.
38. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2010;86(6):588-610. Epub 2010/06/17.
39. Donate LE, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, Blundell TL. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein science: a publication of the Protein Society. 1994;3(12):2378-94. Epub 1994/12/01.
40. Comperat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, et al. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. The Journal of urology. 2008;179(3):868-72; discussion 72. Epub 2008/01/29.
41. Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. British journal of cancer. 2005;92(10):1906-14. Epub 2005/05/05.
42. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental cell research. 2003;288(2):382-9. Epub 2003/08/14.
43. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000;19(27):3041-9. Epub 2000/06/29.
44. Zhao S, Cao L, Freeman JW. Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Oncogenesis. 2013;2:e76. Epub 2013/10/09.
45. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Molecular and cellular biology. 1996;16(12):7072-83. Epub 1996/12/01.
46. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer research. 2010;70(3):1130-40. Epub 2010/01/28.
47. Jaquish DV, Yu PT, Shields DJ, French RP, Maruyama KP, Niessen S, et al. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Carcinogenesis. 2011;32(8):1151-6. Epub 2011/05/14.
48. Keller J, Nimnual AS, Shroyer KR, Joy C, Ischenko I, Chandler CS, et al. Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma. British journal of cancer. 2013;109(2):482-92. Epub 2013/06/27.
49. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 2011;30(33):3625-35. Epub 2011/03/23.
50. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(31):12909-14. Epub 2009/07/02.
51. Al Moustafa AE. Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer. Cell adhesion & migration. 2013;7(5):424-5. Epub 2013/10/25.
52. Thangasamy A, Rogge J, Ammanamanchi S. Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells. The Journal of biological chemistry. 2008;283(9):5335-43. Epub 2008/01/01.
53. Dortet L, Veiga E, Bonazzi M, Cossart P. CD44-independent activation of the Met signaling pathway by HGF and InlB. Microbes and infection/Institut Pasteur. 2010;12(12-13):919-27. Epub 2010/07/31.
54. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes & development. 2002;16(23):3074-86. Epub 2002/12/05.
55. Ni S, Zhao C, Feng GS, Paulson RF, Correll PH. A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Molecular and cellular biology. 2007;27(10):3708-15. Epub 2007/03/14.
56. Liu Y, Liu JH, Chai K, Tashiro S, Onodera S, Ikejima T. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. The Journal of pharmacy and pharmacology. 2013;65(11):1622-42. Epub 2013/10/10.
57. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood. 1992;80(10):2454-7. Epub 1992/11/15.
58. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, et al. MET signaling regulates glioblastoma stem cells. Cancer research. 2012;72(15):3828-38. Epub 2012/05/24.
59. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(24):9951-6. Epub 2011/06/02.
60. Nishida S, Hirohashi Y, Torigoe T, Inoue R, Kitamura H, Tanaka T, et al. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer science. 2013;104(4):431-6. Epub 2013/01/17.
61. Herreros-Villanueva M, Zubia-Olascoaga A, Bujanda L. c-Met in pancreatic cancer stem cells: therapeutic implications. World journal of gastroenterology: WJG. 2012;18(38):5321-3. Epub 2012/10/20.
62. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. British journal of cancer. 2007;97(3):368-77. Epub 2007/08/02.
63. Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin. Human pathology. 2009;40(4):496-504. Epub 2009/01/06.
64. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Human pathology. 2000;31(2):185-92. Epub 2000/02/24.
65. Baschnagel AM, Williams L, Hanna A, Chen PY, Krauss DJ, Pruetz BL, et al. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. International journal of radiation oncology, biology, physics. 2014;88(3):701-7. Epub 2014/02/14.
66. Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, et al. Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes & cancer. 2013;4(7-8):247-60. Epub 2013/10/30.
67. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014;5(7):1837-45. Epub 2014/04/20.
68. Thomas RM, Jaquish DV, French RP, Lowy AM. The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells. Pancreas. 2010;39(3):301-7. Epub 2010/04/02.
69. Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R, Wang MH. Sustained Expression of the RON Receptor Tyrosine Kinase by Pancreatic Cancer Stem Cells as a Potential Targeting Moiety for Antibody-Directed Chemotherapeutics. Molecular pharmaceutics. 2011. Epub 2011/10/22.
70. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance. Pharmacology & therapeutics. 2014;142(3):316-38. Epub 2014/01/05.
71. Medova M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, et al. MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. Genes & cancer. 2010;1(10):1053-62. Epub 2011/07/23.
72. Rimassa L, Personeni N, Simonelli M, Santoro A. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol. 2013;9(2):153-65. Epub 2013/02/19.
73. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The lancet oncology. 2013;14(1):55-63. Epub 2012/11/28.
74. Lee SJ, Lee J, Sohn I, Mao M, Kai W, Park CK, et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer research. 2013;33(11):5179-86. Epub 2013/11/14.
75. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(10):1667-74. Epub 2009/03/04.
76. Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, et al. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PloS one. 2013;8(12):e84700. Epub 2014/01/05.
77. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. The American journal of pathology. 2010;177(1):415-23. Epub 2010/05/22.
78. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(24):3307-15. Epub 2011/07/20.
79. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clinical lung cancer. 2012;13(5):391-5. Epub 2012/03/24.
80. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(2):181-6. Epub 2012/12/06.
81. Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, et al. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 2014;5(19):9150-68. Epub 2014/09/07.
82. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(52):20932-7. Epub 2007/12/21.
83. Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PloS one. 2013;8(7):e69992. Epub 2013/08/08.
84. Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer letters. 2013;340(1):43-50. Epub 2013/07/03.
85. Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, et al. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. International journal of oncology. 2013;42(2):535-42. Epub 2012/12/13.
86. Grunwald V, Merseburger AS. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. OncoTargets and therapy. 2012;5:111-7. Epub 2012/07/13.
87. Funakoshi T, Latif A, Galsky MD. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. Cancer treatment reviews. 2014;40(5):636-47. Epub 2014/03/19.
88. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer cell. 2009;15(3):232-9. Epub 2009/03/03.
89. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer cell. 2009;15(3):220-31. Epub 2009/03/03.
90. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer discovery. 2012;2(3):270-87. Epub 2012/05/16.